UBS Raises Insulet Price Target to $171 From $150, Keeps Neutral Rating
UBS adjusted its price target on Insulet to $171 from $150 and maintained a neutral rating.
UBS adjusted its price target on Insulet to $171 from $150 and maintained a neutral rating.